12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

PAM50-based gene expression test for breast cancer regulatory update

NanoString said it received CE Mark approval for its PAM50-based gene expression test for breast cancer to detect probability of breast cancer recurrence....

Read the full 93 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >